PRF Technologies Ltd

PRFX

Market cap $3.16M

Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch

TEL AVIV, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced that its DeepSolar business unit will participate in Energy Trading Week Europe 2026, taking place September 24–25, 2026, at the Business Design Centre in London.

New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial Launch New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial Launch

Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch

Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential as a long-acting, single-administration post-operative analgesic Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential as a long-acting, single-administration post-operative analgesic

Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance exposure, storage optimization and real-time market decision-making Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance exposure, storage optimization and real-time market decision-making

Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile

Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation

LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today provided a business update for the year ended December 31, 2025, in conjunction with the filing of its Annual Report on Form 20-F.

TEL AVIV, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced a commercial collaboration agreement with Blade Ranger Ltd.